...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans
【24h】

Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans

机译:适用于药物 - 药物相互作用研究的内源化合物的研究,涉及肾脏有机阴离子转运蛋白,OAT1和OAT3,人类

获取原文
获取原文并翻译 | 示例

摘要

This study was a comprehensive analysis of metabolites in plasma and urine specimens from subjects who received probenecid, a potent inhibitor of renal organic anion transporters (OATs). Taurine and glycochenodeoxycholate sulfate (GCDCA-S) could be identified using authentic standards. Probenecid had no effect on the area under the plasma-concentration time curves of taurine and GCDCA-S, whereas it significantly inhibited their urinary excretion in a dose-dependent manner. Probenecid at 500, 750, and 1500 mg orally decreased the renal clearance (CLR) values of taurine and GCDCA-S by 45% and 60%, 59% and 79%, and 70% and 88%, respectively. The CLR values correlated strongly (r > 0.96) between the test compounds (benzylpenicillin, 6 beta-hydroxycortisol, taurine, and GCDCA-S). Taurine and GCDCA-S were substrates of OAT1 and OAT3, with K-m values of 379 +/- 58 and 64.3 +/- 3.9 mu M, respectively. The K-i values of probenecid for the OAT1- and OAT3-mediated uptake of taurine and GCDCA-S (9.49 +/- 1.27 and 7.40 +/- 0.70 mu M, respectively) were similar to those of their typical substrate drugs. The magnitude of the reduction in the CLR of taurine and GCDCA-S by probenecid could be reasonably explained using the geometric mean values of unbound probenecid concentration and K-i values. These results suggest that taurine and GCDCA-S can be used as probes for evaluating pharmacokinetic drug-drug interactions involving OAT1 and OAT3, respectively, in humans.
机译:本研究综合分析了接受丙烯酸的受试者的血浆和尿标本中的代谢物,肾脏有机阴离子转运蛋白(燕麦)的有效抑制剂。可以使用真实标准识别牛磺酸和甘油糖烷苯酚硫酸盐(GCDCA-S)。 Probenecid对牛磺酸和GCDCA-S等血浆浓度时间曲线下的区域没有影响,而它以剂量依赖性方式显着抑制其尿液排泄。 500,750和1500毫克的丙烯酸口服将牛磺酸和GCDCA-S的肾间隙(CLR)值分别降低45%和60%,59%和79%,70%和88%。在测试化合物(苄基甲霉素,6β-羟基硅藻,牛磺酸和GCDCA-S之间,CLR值强烈(R> 0.96)相关。牛磺酸和GCDCA-S分别是澳鹿和卫生菌的底物,K-M值分别为379 +/- 58和64.3 +/-3.9μm。牛磺酸和GCDCA-S的oat1-和oat3介导的丙烯酸的K-I值(分别为9.49 +/- 1.27和7.40 +/- 0.70 mu m)与其典型的底物药物相似。可以使用丙烯酸的牛磺酸和GCDCA-S的CLR的减少的幅度使用未结合丙烯酸浓度和K-I值的几何平均值来合理地解释。这些结果表明,牛磺酸和GCDCA-S可用作评估涉及人类的药代动力学药物 - 药物相互作用的探针。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号